Clostridium difficile: Emergence of hypervirulence and fluoroquinolone resistance

Infection

Volumn 35, Issue 5, 2007, Pages 300-307

  Razavi, B ^a   Apisarnthanarak, A ^b   Mundy, L M ^c  

^a West Georgia Medical Center   (United States)

^b THAMMASAT UNIVERSITY   (Thailand)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FUSIDIC ACID; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLON RESECTION; DIARRHEA; DRUG DOSE COMPARISON; DRUG TOLERABILITY; EPIDEMIC; GENE DELETION; GENE LOCUS; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR EPIDEMIOLOGY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; RECOMMENDED DRUG DOSE; REGULATOR GENE; REVIEW; SACCHAROMYCES BOULARDII;

ADULT; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DIARRHEA; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGY, MOLECULAR; FLUOROQUINOLONES; HUMANS; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; VIRULENCE;

EID: 34848889558     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6113-0     Document Type: Review

References (96)

1. Hall IC, O'Toole E: Intestinal flora in new-born infants. Am J Dis Child 1935; 49: 390-402.
2. Tedesco FJ, Barton RW, Alpers DH: Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81: 429-433.
3. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB: Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-534.
4. Kelly CP, Pothoulakis C, LaMont JT: Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262.
5. Bartlett JG: Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-339.
6. Anand A, Glatt AE: Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109-113.
7. Moskowitz M, Bartlett JG: Recurrent pseudomembranous enterocolitis unassociated with pilot antibiotic therapy. Arch Intern Med 1981; 141: 663-664.
8. Bartlett JG, Gorbach SL: Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med 1979; 22: 646-656.
9. Centers for Disease Control and Prevention (CDC) Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1201-1205.
10. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-280.
11. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441.
12. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 8: 2442-2449.
13. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084.
14. Akerlund T, Svenungsson B, Lagergren A, Burman LG: Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006; 44: 353-358.
15. Fekety R, Shah AB: Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 6: 71-75.
16. Borriello SP: The influence of the normal flora on Clostridium difficile colonisation of the gut. Ann Med 1990; 22: 61-67.
17. Borriello SP, Barclay FE: An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol 1986; 21: 299-309.
18. Bartlett JG: Management of Clostridium difficile infection and other antibiotic-associated diarrhoeas. Eur J Gastroenterol Hepatol 1996; 8: 1054-1061.
19. Barbut F, Lalande V, Burghoffer B, Thien HV, Grimprel E, Petit JC: Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol 2002; 40: 2079-2083.
20. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, LaMont JT: Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995; 95: 2004-2011.
21. Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, Lyerly DM, Popoff MR, Rood J, Sonenshein AC, Thelestam M, Wren BW, Wilkins TD, von Eichel-Streiber C: Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol 2005; 54: 113-117.
22. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA (eds): Clostridium difficile. In: Medical Microbiology. Mosby-Year book, Inc., St Louis 1998, pp 296-307.
23. Geric B, Rubnik M, Gerding DN, Grabner M, Johnson S: Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 2004; 53: 887-894.
24. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerdon B, Popoff M: Production of actin-specific ADP-ribosyltransferase (binding toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186: 307-312.
25. Spigaglia P, Mastrantonio P: Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002; 40: 3470-3475.
26. McFarland LV, Mulligan ME, Kwok RY, Stamm WE: Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-210.
27. Kelly CP, LaMont JT: Clostridium difficile infection. Annu Rev Med 1998; 49: 375-390.
28. Warny M, Vaerman JP, Avesani V, Delmee M: Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384-389.
29. Kim PH, Iaconis JP, Rolfe RD: Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987; 55: 2984-2992.
30. Kyne L, Warny M, Qamar A, Kelly CP: Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-193.
31. Kyne L, Warny M, Qamar A, Kelly CP: Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
32. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A: Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633-637.
33. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN: Nosocomial Clostridium difficile colonisation and disease. Lancet 1990; 336: 97-100.
34. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R: Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169: 127-133.
35. Polk RE, Oinonen M, Pakyz A: Epidemic Clostridium difficile. N Engl J Med 2006; 354: 1199-1203.
36. Viscidi R, Willey S, Bartlett JG: Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981; 81: 5-9.
37. Bartlett JG: Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15: 573-581.
38. Gerding DN: Disease associated with Clostridium difficile infection. Ann Intern Med 1989; 110: 255-257.
39. Pepin J, Routhier S, Gagnon S, Brazeau I: Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42: 758-764.
40. Barbut F, Petit JC: Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001; 7: 405-410.
41. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr: Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459-477.
42. Malamou-Ladas H, O'Farrell S, Nash JQ, Tabaqchali S: Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol 1983; 36: 88-92.
43. Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J Jr, Waters D: Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143: 42-50.
44. Johnson S, Gerding DN, Olson MM, Weiler MD, Hughes RA, Clabots CR, Peterson LR: Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990; 88: 137-140.
45. Brooks SE, Veal RO, Kramer M, Dore L, Schupf N, Adachi M: Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with singleuse disposables. Infect Control Hosp Epidemiol 1992; 13: 98-103.
46. Mayfield JL, Leet T, Miller J, Mundy LM: Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31: 995-1000.
47. Apisarnthanarak A, Zack JE, Mayfield JL, Freeman J, Dunne WM, Little JR, Mundy LM, Fraser VJ: Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile. Clin Infect Dis 2004; 39: 601-602.
48. Gerding DN, Olson MM, Peterson LR, Teasley DG, Gebhard RL, Schwartz ML, Lee JT Jr: Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986; 146: 95-100.
49. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F: Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991; 35: 208-210.
50. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C: Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990; 11: 283-290.
51. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
52. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D: Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-472.
53. Al-Barrak A, Embil J, Dyck B, Olekson K, Nicoll D, Alfa M, Kabani A: An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep 1999; 1: 65-69.
54. Kuijper EJ, de Weerdt J, Kato H, Kato N, van Dam AP, van der Vorm ER, Weel J, van Rheenen C, Dankert J: Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis 2001; 20: 528-534.
55. Pituch H, van den Braak N, van Leeuwen W, van Belkum A, Martirosian G, Obuch-Woszczatynski P, Luczak M, Meisel-Mikolajczyk F: Clonal dissemination of a toxin-A-negative/toxin-Bpositive Clostridium difficile strain from patients with antibioticassociated diarrhea in Poland. Clin Microbiol Infect 2001; 7: 442-446.
56. Rupnik M, Kato N, Grabnar M, Kato H: New types of toxin Anegative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 2003; 41: 1118-1125.
57. van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, Kuijper EJ: Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol 2004; 42: 1035-1041.
58. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S: Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 2004; 53: 887-894.
59. Drudy D, Fanning S, Kyne L: Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007; 11: 5-10.
60. Savidge TC, Pan WH, Newman P, O'brien M, Anton PM, Pothoulakis C: Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003; 125: 413-420.
61. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK: Infectious Diseases Society of America: practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32: 331-351.
62. Fekety R: Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739-750.
63. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT Jr: Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 1043-1046.
64. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W: Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-818 (Erratum, Clin Infect Dis 1996; 23: 423).
65. ASHP therapeutic position statement of the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm 1998; 55:1401-1411.
66. Fernandez A, Anand G, Freidenberg F: Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38: 414-418.
67. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Rossignal JF: Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 21-27.
68. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C: Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-1597.
69. McFarland LV, Elmer GW, Suraciwz CM: Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775.
70. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-1918 (Erratum, JAMA 1994; 272: 518).
71. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012-1017.
72. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C: Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 547-552.
73. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammad R, Dow S, Weiss K, Simon S, John JF, Garber G, Chasar-Taber S, Davidson DMTolevamer Study Investigator Group Tolevamer, a novel non-antibiotic polymer, compared with vancomycin, in the treatment of mild to moderately severe C lostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411-420.
74. Bolton RP, Culshaw MA: Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-1172.
75. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ: Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-1590.
76. Jang SS, Hansen LM, Breher JE, Riley DA, Magdesian KG, Madigan JE, Tang YJ, Silva J Jr, Hirsh DC: Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 1997; 25: S266-S267.
77. Browne RA, Fekety R Jr, Silva J Jr, Boyd DI, Work CO, Abrams GD: The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J 1977; 141: 183-192.
78. Geraci JE, Heilman FR, Nichols DR, Weilman WE, Ross GT: Some laboratory and clinical experiences with a new antibioitic, vancomycin. Staff Meet Mayo Clin 1956; 31: 564-582.
79. Wilcox MH: Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 53: 882-884.
80. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ: Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49: 640-645.
81. Beales IL: Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 2002; 51: 456.
82. Apisarnthanarak A, Razavi B, Mundy LM: Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35: 690-696.
83. Apisarnthanarak A, Khoury H, Reinus WR, Crippin JS, Mundy LM: Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med 2002; 112: 328-329.
84. Lipsett PA, Samantaray DK, Tam ML, Bartlett JG, Lillemoe KD: Pseudomembranous colitis: a surgical disease? Surgery 1994; 116: 491-496.
85. Aas J, Gessert CE, Bakken JS: Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-585.
86. Schwan A, Sjolin S, Trottestam U, Aronsson B: Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16: 211-215.
87. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE: Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47: 1620-1626.
88. Torres JF, Lyerly DM, Hill JE, Monath TP: Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995; 63: 4619-4627.
89. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB: Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 1997; 65: 2941-2949.
90. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW: Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 1999; 67: 2145-2152.
91. Pavliakova D, Moncrief JS, Lyerly DM, Schiffman G, Bryla DA, Robbins JB, Schneerson R: Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect Immun 2000; 68: 2161-2166.
92. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP: Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71: 1608-1610.
93. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP: Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128: 764-770.
94. Kyne L, Hamel MB, Polavaram R, Kelly CP: Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-353.
95. Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, Kollef MH, Mundy LM: Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007; 28: 123-130.
96. Giannasca PJ, Warny M: Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004; 22: 848-856.